| Literature DB >> 32660104 |
Mathilde Bouché1, Bruno Vincent2, Thierry Achard1, Stéphane Bellemin-Laponnaz1.
Abstract
A series of octahedral platinum(IV) complexes functionalized with both N-heterocyclic carbene (NHC) ligands were synthesized according to a straightforward procedure and characterized. The coordination sphere around the metal was varied, investigating the influence of the substituted NHC and the amine ligand in trans position to the NHC. The influence of those structural variations on the chemical shift of the platinum center were evaluated by 195Pt NMR. This spectroscopy provided more insights on the impact of the structural changes on the electronic density at the platinum center. Investigation of the in vitro cytotoxicities of representative complexes were carried on three cancer cell lines and showed IC50 values down to the low micromolar range that compare favorably with the benchmark cisplatin or their platinum(II) counterparts bearing NHC ligands.Entities:
Keywords: 195Pt NMR; N-heterocyclic carbene; metal complexes; platinum
Mesh:
Substances:
Year: 2020 PMID: 32660104 PMCID: PMC7397185 DOI: 10.3390/molecules25143148
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1General synthesis of the platinum (II) and platinum (IV) complexes.
Scheme 2Molecular structure of the N-heterocyclic carbene (NHC)-Pt(II) references.
Scheme 3Molecular structure of the NHC-Pt(IV) complexes.
Figure 1Molecular structure of complex 15. Selected bond distances (Å) and angles (deg): C(1)-Pt(1), 2.057(8); Br(1)-Pt(1), 2.4882(8); Br(2)-Pt(1), 2.4657(8); Br(3)-Pt(1), 2.4615(8); Br(4)-Pt, 2.4839(8); N(3)-Pt(1), 2.128(6); C(1)-Pt(1)-N(3), 179.2(3); C(1)-Pt(1)-Br(3), 92.9(2); N(3)-Pt(1)-Br(3), 87.10(16); Br(2)-Pt(1)-Br(3), 86.10(3); Br(1)-Pt(1)-Br(4), 177.05(3).
Half-inhibitory concentrations IC50 (µM) of the selected complexes toward the HCT116, MCF7 and PC3 cancer cells.
| Complex Number | Structure | IC50 (µM) | IC50 (µM) | IC50 (µM) |
|---|---|---|---|---|
|
| (NH3)2PtCl2 | 3.57 ± 0.1 | 4.15 ± 0.7 | 3.10 ± 0.2 |
|
| (NHC)PtBr2(pyr) | 5.44 ± 1 | 7.73 ± 1 | 5.35 ± 1.6 |
|
| (NHC)PtBr2(DMSO) | >100 | >100 | >100 |
|
| (NHC)PtCl2(DMSO) | 63 ± 5 | 80 ± 13 | 65 ± 6 |
|
| (NHC)PtCl2(pyr) | 3.78 ± 0.1 | 3.48 ± 1 | 4.40 ± 0.9 |
|
| (NHC)PtBr4(amine) | 7.5 ± 0.3 | 23 ± 5 | 10 ± 1 |
|
| 14 ± 2 | 5 ± 1 | 5 ± 1 | |
|
| 11 ± 0.3 | 3 ± 0.7 | 2 ± 0.5 | |
|
| 81.09 ± 2 | 17.22 ± 1.8 | 5.42 ± 0.5 | |
|
| 5 ± 1 | 4 ± 0.2 | 5 ± 1 | |
|
| (NHC)PtCl4(amine) | 0.5 ± 0.03 | 0.5 ± 0.09 | 1 ± 0.1 |
|
| 1.48 ± 0.2 | 1.78 ± 0.6 | 1.31 ± 0.2 |
1 HCT116, colon cancer cells; MCF7, breast carcinoma; PC3, prostate adenocarcinoma. (After 72 h of incubation; stock solutions in DMSO for all complexes; stock solution in H2O for cisplatin).
Chemical shift evolution of the Pt signal as a function of the metal oxidation state, the coordination sphere of the metal and the NHC substituents (external reference for 195Pt: H2PtCl6 in D2O: δPt = 0 ppm).
| Complex | Ox. State | δPt (ppm) | δC (ppm) |
|---|---|---|---|
|
| +II | −4313 | 125.1 |
|
| +II | −3814 | 138.2 |
|
| +II | −3356 | 154.7 |
|
| +II | −3351 | n.o. |
|
| +II | −3304 | n.o. |
|
| +IV | −2196 | n.o. |
|
| +IV | −2168 | 113.4 |
|
| +IV | −2168 | 115.2 |
|
| +IV | −2167 | 133.9 |
|
| +IV | −2083 | 124.6 |
|
| +IV | −2081 | n.o. |
|
| +IV | −2080 | 112.7 |
|
| +IV | −2079 | 115.4 |
|
| +IV | −2070 | n.o. |
|
| +IV | −2067 | n.o. |
|
| +IV | −2063 | 110.8 |
|
| +IV | −2058 | 110.7 |
|
| +IV | −2048 | 109.3 |
|
| +IV | −2040 | 109.2 |
|
| +IV | −2032 | n.o. |
|
| +IV | −1901 | n.o. |
|
| +IV | −883 | n.o. |
|
| +IV | −853 | n.o. |
|
| +IV | −825 | 112.9 |
|
| +IV | −810 | 111.5 |
|
| +IV | −795 | n.o. |
1 n.o.: not observed.